PMID- 33329527
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Intratumor Heterogeneity of HLA-G Expression in Cancer Lesions.
PG  - 565759
LID - 10.3389/fimmu.2020.565759 [doi]
LID - 565759
AB  - Signaling pathway between human leukocyte antigen (HLA)-G and immune inhibitory 
      receptors immunoglobulin-like transcript (ILT)-2/4 has been acknowledged as one 
      of immune checkpoints, and as a potential target for cancer immunotherapy. Like 
      other immune checkpoints, inter- and even intratumor heterogeneity of HLA-G could 
      render a rather complexity for HLA-G-target immunotherapy. However, little 
      information for intratumor heterogeneity of HLA-G is available. In this study, 
      HLA-G expression in a serial section of colorectal cancer (CRC) lesions from 
      three CRC patients (each sample with serial section of 50 slides, 10 randomized 
      slides for each antibody), three different locations within a same sample (five 
      CRC), and three case-matched blocks that each includes 36 esophageal cancer 
      samples, were evaluated with immunohistochemistry using anti-HLA-G antibodies 
      (mAbs 4H84, MEM-G/1 and MEM-G/2 probing for all denatured HLA-G isoforms, 5A6G7, 
      and 2A12 probing for denatured HLA-G5 and HLA-G6 isoforms). Our results revealed 
      that, in addition to the frequently observed inter-tumor heterogeneity, 
      intratumor heterogeneous expression of HLA-G is common in different areas within 
      a tumor in CRC and esophageal cancer samples included in this study. Moreover, 
      percentage of HLA-G expression probed with different anti-HLA-G antibodies also 
      varies dramatically within a tumor. Given HLA-G has been considered as an 
      important immune checkpoint, intratumor heterogeneity of HLA-G expression, and 
      different specificity of anti-HLA-G antibodies being used among studies, 
      interpretation and clinical significance of HLA-G expression in cancers should be 
      with caution.
CI  - Copyright (c) 2020 Zhang, Lin, Han, Zhang, Chen, Ye, Zhou, Xu, Gan and Yan.
FAU - Zhang, Xia
AU  - Zhang X
AD  - Biological Resource Center, TaiZhou Hospital of Zhejiang Province, Taizhou Enze 
      Medical Center (Group), LinHai, China.
FAU - Lin, Aifen
AU  - Lin A
AD  - Biological Resource Center, TaiZhou Hospital of Zhejiang Province, Taizhou Enze 
      Medical Center (Group), LinHai, China.
FAU - Han, Qiu-Yue
AU  - Han QY
AD  - Biological Resource Center, TaiZhou Hospital of Zhejiang Province, Taizhou Enze 
      Medical Center (Group), LinHai, China.
FAU - Zhang, Jian-Gang
AU  - Zhang JG
AD  - Biological Resource Center, TaiZhou Hospital of Zhejiang Province, Taizhou Enze 
      Medical Center (Group), LinHai, China.
FAU - Chen, Qiong-Yuan
AU  - Chen QY
AD  - Biological Resource Center, TaiZhou Hospital of Zhejiang Province, Taizhou Enze 
      Medical Center (Group), LinHai, China.
FAU - Ye, Yao-Han
AU  - Ye YH
AD  - Biological Resource Center, TaiZhou Hospital of Zhejiang Province, Taizhou Enze 
      Medical Center (Group), LinHai, China.
FAU - Zhou, Wen-Jun
AU  - Zhou WJ
AD  - Biological Resource Center, TaiZhou Hospital of Zhejiang Province, Taizhou Enze 
      Medical Center (Group), LinHai, China.
FAU - Xu, Hui-Hui
AU  - Xu HH
AD  - Medical Research Center, TaiZhou Hospital of Zhejiang Province, Taizhou Enze 
      Medical Center (Group), LinHai, China.
FAU - Gan, Jun
AU  - Gan J
AD  - Medical Research Center, TaiZhou Hospital of Zhejiang Province, Taizhou Enze 
      Medical Center (Group), LinHai, China.
FAU - Yan, Wei-Hua
AU  - Yan WH
AD  - Medical Research Center, TaiZhou Hospital of Zhejiang Province, Taizhou Enze 
      Medical Center (Group), LinHai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (HLA-G Antigens)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Colorectal Neoplasms/*immunology
MH  - Esophageal Neoplasms/*immunology
MH  - Female
MH  - HLA-G Antigens/*immunology
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC7717930
OTO - NOTNLM
OT  - HLA-G
OT  - antibody
OT  - colorectal cancer
OT  - esophageal cancer
OT  - heterogeneity
OT  - isoform
OT  - tumor
EDAT- 2020/12/18 06:00
MHDA- 2021/05/18 06:00
PMCR- 2020/01/01
CRDT- 2020/12/17 05:50
PHST- 2020/06/03 00:00 [received]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/12/17 05:50 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.565759 [doi]
PST - epublish
SO  - Front Immunol. 2020 Nov 19;11:565759. doi: 10.3389/fimmu.2020.565759. eCollection 
      2020.